Strictly regulating an industry with high demand, like healthcare or vaping, often backfires. Instead of eliminating risk, it pushes consumers and providers into a "parallel" gray market that is less regulated, less coordinated, and ultimately more harmful. The intended consumer protection fails because the regulated system becomes too difficult to operate within, forcing activity outside the "kingdom walls."

The argument against adopting lower foreign drug prices is framed as a national security imperative. Proponents argue that such price controls would slash U.S. R&D investment, allowing China to dominate the bio-pharma sector and potentially weaponize future drug supply chains in a crisis.

A paradoxical market reality is that sectors with heavy government involvement, like healthcare and education, experience skyrocketing costs. In contrast, less-regulated, technology-driven sectors see prices consistently fall, suggesting a correlation between intervention and price inflation.

Mark Cuban reveals the primary barrier to making generic drugs in the US isn't production cost, which can be cheaper than overseas, but the prohibitive FDA application fees costing hundreds of thousands per drug.

The requirement for prescriptions for many safe drugs stems from a paternalistic medical culture that distrusts patients, not from genuine safety concerns. This drives up costs and creates unnecessary barriers, similar to how the establishment initially resisted home pregnancy and COVID tests.

While the FDA is often blamed for high trial costs, a major culprit is the consolidated Clinical Research Organization (CRO) market. These entrenched players lack incentives to adopt modern, cost-saving technologies, creating a structural bottleneck that prevents regulatory modernization from translating into cheaper and faster trials.

Beyond funding and regulatory hurdles, Europe's restrictive drug pricing environment is a fundamental threat. It discourages pharmaceutical companies, including Europe's own, from investing in the region as they prioritize the more profitable US market. This ultimately undermines the entire local R&D ecosystem.

To minimize risk, government contracts often require bidders to have prior experience building the exact same system. This seemingly prudent rule creates a catch-22, barring new entrants and locking in a small number of incumbents who can then dominate the market and inflate prices.

Regulatory capture is not an abstract problem. It has tangible negative consequences for everyday consumers, such as the elimination of free checking accounts after the Dodd-Frank Act was passed, or rules preventing physicians from opening new hospitals, which stifles competition and drives up costs.